Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection

NCT02281266 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

360

Enrollment

OTHER

Sponsor class

Conditions

Curable Hepatitis B Virus-Related Hepatocellular Carcinoma

Interventions

PROCEDURE: curative resection
DRUG: thymalfasin
DRUG: nucleoside analog (suggest to use entecavir)

Sponsor

Jia Fan

Collaborators

[object Object]